Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

Phase 2

Active, not recruiting

• Conditions: Chronic Kidney Diseases; Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus
• Interventions: Biological: Renal Autologous Cell Therapy (REACT)

• Registration Number: NCT05018416
• Lead Sponsor: Prokidney

Brief Summary

The purpose of this study is to assess the safety, efficacy, and durability of up to two REACT injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with T1DM or T2DM and CKD.

Detailed Description

The objective of this study is to assess the safety, efficacy, and durability of up to two REACT injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with T1DM or T2DM and CKD:

* Cohort 1: Two scheduled REACT injections given 3 months (+60 days) with at least 18- month follow-up

* Cohort 2: One scheduled REACT injection with a possible second REACT injection, no less than 3 months after the first one, within 30 days (+30 days) of meeting a renal function redose trigger (triggered up to 15 months following the first REACT injection).

Both cohorts will be followed for 18 months after the final REACT injection. If a Cohort 2 subject does not meet a trigger, the subject will be followed for at least 18 months after the first injection.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study Start: 2021-07-27
• Study First Submitted: 2021-08-17
• Study First Submitted QC: 2021-08-18
• Study First Posted: 2021-08-24
• Status Verified: 2023-05
• Last Update Submitted: 2024-01-10
• Last Update Posted: 2024-01-12
• Primary Completion: 2026-06-30
• Study Completion: 2026-09-22

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 53

Inclusion Criteria

1. Male or female aged 30 to 80 years, inclusive, on the date informed consent is signed.
2. Clinical diagnosis of T1DM or T2DM, controlled per institutional standard of care.
3. The subject has a clinical diagnosis of diabetic nephropathy as the underlying cause of renal disease (diagnosis does not have to be confirmed via renal biopsy).
4. The subject has a serum glycosylated hemoglobin (HbA1c) level less than 10% at the Screening Visit.
5. The subject has a documented clinical diagnosis of an eGFR between 20 and 50 mL/min/1.73m² inclusive not requiring renal dialysis.

Read More

Exclusion Criteria

1. The subject has a history of renal transplantation.

2. The subject has a mean systolic blood pressure greater than or equal to 140 mmHg and/or mean diastolic blood pressure greater than or equal to 90 mmHg at screening.

   Subjects with blood pressure outside of this range prior to biopsy/injection may continue if approved by the Medical Monitor.

3. The subject has hemoglobin levels less than 10 g/dL and is not responsive to the standard medical intervention for CKD-related anemia prior to randomization.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2 REACT injections	Renal Autologous Cell Therapy (REACT)	Cohort 1 subjects will receive 2 REACT injections in the biopsied and non-biopsied contralateral kidneys 3 months apart (+60 days).
1 REACT Injection	Renal Autologous Cell Therapy (REACT)	Cohort 2 subjects will receive 1 REACT injection into the biopsied kidney and if a pre-defined trigger is met, will undergo a second REACT injection into the contralateral kidney.

Primary Outcome Measures

Name	Time	Method
Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.	Screening thru 18 months after the last injection of study drug
Improvement in renal function progression rate as indicated by the change from pre-injection baseline value in total (acute + chronic) slope of estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equation	Screening thru month 28

Trial Locations

Locations (5)

Nephrology Associates; 🇺🇸 Newark, Delaware, United States

Nephrology and Hypertension Associates Ltd - Frenova; 🇺🇸 Tupelo, Mississippi, United States

Kidney Associates of Colorado, P.C. - Frenova; 🇺🇸 Denver, Colorado, United States

Boise Kidney and Hypertension Institute - Frenova; 🇺🇸 Nampa, Idaho, United States

Paragon Health, PC d/b/a Nephrology Center, PC - Frenova; 🇺🇸 Kalamazoo, Michigan, United States